We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Sep 2022
  • Code : CMI5199
  • Pages :184
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Two outbreaks of a disease resembling the pox in colonies of monkeys kept for research led to the discovery of monkeypox in 1958. The monkeypox virus is the cause of this rare viral disease. Monkeypox is a type of Zoonotic disease, which are transmitted from animals to humans. The virus that causes smallpox and monkeypox both belong to the same family of viruses. However, it is less severe as compared to smallpox. The symptoms of monkeypox are similar to smallpox symptoms, but are milder and generally non-fatal.

Central and western Africa are more prone to monkeypox. However, due to 2022 outbreak, western and European region are also susceptible to monkeypox disease.  

Global monkeypox treatment market is estimated to be valued at US$ 70.4 Million in 2022 and expected to reach US$ 258.6 million by 2030, witnessing a CAGR of 17.7 % over the forecast period (2022-2030).

Figure 1. Global Monkeypox Treatment Market Share (%), By Region, 2022

MONKEYPOX TREATMENT MARKET

To learn more about this report, request a free sample copy

Increase in the prevalence of monkeypox disease is expected to drive growth of the global monkeypox treatment market

The increasing incidence of monkeypox disease is expected to drive the demand for new drugs and vaccines for the treatment of this disease. This is further expected to drive the global monkeypox treatment market growth over the forecast period.

For instance, according to data published by Centers for Disease Control and Prevention, till 9 August 2022, there are confirmed 31,800 total cases of monkeypox, worldwide, out of which 31,425 are in countries that have not historically reported monkeypox. While, 375 in countries that have historically reported monkeypox.

Moreover, according to a study published in the New England Journal of Medicine, it was found that between April and June 2022, 98% of the monkeypox infections in 16 countries across the globe were in men who have sex with men and LGBT communities.

Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 70.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 17.7% 2030 Value Projection: US$ 258.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment Type: Prophylactic (Vaccines), Therapeutics (Tecovirimat, Brincidofovir, Cidofovir)
  • By Route of Administration: Oral, Injectable
  • By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
Companies covered:

SIGA Technologies Inc., Chimerix, Inc., Bavarian Nordic, Sanofi SA., Emcure Pharma, Jinan Jinda Pharmaceutical Chemistry Co., Ltd. 

Growth Drivers:
  • Increase in the prevalence of monkeypox.
  • Increasing in the demand for vaccines and new treatment for monkeypox
Restraints & Challenges:
  • Side effects of monkeypox drugs

Figure 2. Global Monkeypox Treatment Market Share (%) Analysis, By Treatment Type, 2022

MONKEYPOX TREATMENT MARKET

To learn more about this report, request a free sample copy

Increasing in the demand for vaccines and new treatment for monkeypox is expected to drive the growth of the global monkeypox treatment market.

For instance, on August 4, 2022, the U.S. Department of Health and Human Services, declared the monkeypox outbreak to be a public health emergency. Due to which there is acceleration in the demand for vaccines and better treatment for monkeypox.

Moreover, according to Centers for Disease Control and Prevention, the demand for the vaccine is outstripping the America’s vaccine supply. Thus, huge demand for vaccines and treatment for monkeypox is expected to drive the growth of global monkeypox treatment market.

Global Monkeypox Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe. The corona virus (COVID 19) pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses in all sectors. Supply chain and manufacturing activities have been disrupted globally, due to lockdowns implemented by governments of countries, restricted movement, and other COVID-19 safety precautions. However, COVID 19 has negligible impact on monkeypox treatment market.  

However, manufacturing sites, which are based in worst hit countries, have been affected severely due to severe shortage of medical resources and raw materials. This has led to global supply chain disruption.

The U.S. Food and Drug Administration (FDA) continues to monitor the supply chain. The Center for Drug Evaluation and Research (CDER) Drug Shortage Staff in 2020 asked manufacturers to evaluate their entire supply chain of various products, ethanol, EDTA (Ethylenediaminetetraacetic acid) and vaccines manufacturing equipment, etc. which in future is expected to improve the supply chain of healthcare products.

Global Monkeypox Treatment Market: Restraint

The major restraint for global monkeypox treatment market is increasing side effects related to the drugs used to treat this disease, thus, this can hinder the growth of global monkeypox treatment market.

Mild upset stomach, dry mouth, decreased concentration and dysphoria are some major side effects of drugs used to treat Monkeypox.

Key Players

Major players operating in the global monkeypox treatment market include SIGA Technologies, Inc., Chimerix, Inc., Bavarian Nordic, Sanofi SA, and Emcure Pharma, Jinan Jinda Pharmaceutical Chemistry Co., Ltd.

Frequently Asked Questions

Global monkeypox treatment market is estimated to be valued at US$ 70.4 Million in 2022 and expected to exhibit a CAGR of 17.7 % between 2022 and 2030.

Increase in the prevalence of monkeypox disease is expected to drive growth of the market.

Prophylactic is the major treatment type in the market.

Side effects such as mild upset stomach, dry mouth, decreased concentration and dysphoria major factor restraining the market growth.

Major players operating in the market include SIGA Technologies, Inc., Chimerix, Inc., Bavarian Nordic, Sanofi SA, and Emcure Pharma, Jinan Jinda Pharmaceutical Chemistry Co., Ltd.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo